Health Innovation

We are de-risking biomedical innovations, turning biomedical knowledge into social and economic value.

Health Innovation Assessment

Mercury Pharmaceuticals

Innovators and start-ups in healthcare and biotech are experts in their innovation’s scientific and technical domain but often struggle with navigating the complex world of the healthcare industry.

If you want to objectively show the advantages and competitiveness of your innovation to potential investors, future users, (reimbursement) payers or even the media, you can greatly benefit from Mercury Pharmaceuticals’s Health Innovation Assessment solution.

By making use of robust methods to collect and analyse data, Health Innovation Assessment (HIA) aims to comprehensively assess the added value of (bio-)medical and healthcare innovations. HIA takes into account true multi-stakeholder perspectives on value assessment and the realm of marketplace decision making.

MERCURY trials

Clinical trials are very important as it allow us to evaluate the effectiveness of new drugs, new devices, preventative strategies or treatment strategies. It also enables us to discover better ways for patients' care.
- Learn more

Cancer

Our mission remains constant as we endeavor to deliver novel medicines to patients with cancer, treating solid tumors with high unmet medical needs in well-defined patient populations that are currently not well supported.
- Learn more

Neuroscience

Whether you're looking to manufacture toxicology batches or cGMP material for clinical trials, we can help you expedite molecules to clinic with full transparency.
- Learn more

STAY INFORMED!

More data, more answers? A 1.9 million-person health study shows why scale has limits

14

Sep 2026

More data, more answers? A 1.9 million-person health study shows why scale has limits

Researchers analyzed phenotypic and linked health-record data from more than 1.9 million adults in Our Future Health, comparing demographic characteristics, disease patterns, clinical associations, and rare-condition case counts with national data and other major cohorts. The cohort's size provides unusually large samples for many common and less common conditions, although its demographic composition and current data sources require careful consideration when interpreting population-level estimates.

READ MORE
APOE genotype helps p-tau217 predict who may develop cognitive impairment sooner

14

Sep 2026

APOE genotype helps p-tau217 predict who may develop cognitive impairment sooner

A pooled analysis of 8,582 adults from seven prospective cohorts found that higher plasma p-tau217 concentrations were associated with greater cognitive impairment risk and earlier progression, with stronger associations among APOE-ε4 carriers. Each 1-SD increase in p-tau217 was associated with a 24% shorter time to cognitive impairment among carriers compared with 13% among non-carriers, suggesting that genetic background can refine the prognostic meaning of this Alzheimer’s disease blood biomarker.

READ MORE
A study of ayahuasca users found a mental health pattern researchers cannot yet explain

13

Sep 2026

A study of ayahuasca users found a mental health pattern researchers cannot yet explain

In a cross-sectional study of 808 Brazilian adults planning to attend ayahuasca ceremonies, greater prior experience with the brew was associated with lower depression, anxiety, and stress scores, as well as higher spiritual well-being and stronger metaphysical beliefs. Because the study was observational and relied on self-reported data, it cannot show that ayahuasca caused these differences.

READ MORE
Cockroaches have a reputation for surviving almost anything, but this diet proved deadly

13

Sep 2026

Cockroaches have a reputation for surviving almost anything, but this diet proved deadly

A laboratory study tested how ultra-processed, unprocessed, and mixed diets affected survival in 127 lobster cockroaches, <em>Nauphoeta cinerea</em>. Cockroaches fed only ultra-processed foods had higher mortality than those given unprocessed or mixed diets, although the study could not determine whether processing, ingredients, nutrition, or differences in food intake caused the effect.

READ MORE

Why Us?

KNOWLEDGE OF RESEARCH ENVIRONMENT

Strong experience in academic research and technology transfer makes us understand your goals and motivations as a technology originator.

UNDERSTANDING INDUSTRIAL NEEDS

Our experience in drug development from discovery to clinical and commercial stages makes us an insider player within the biopharmaceutical industry.

FOCUSED PROJECT MANAGEMENT

Smart approach to project management that helps speed up development stages and decision making.

INVESTMENT CAPABILITY

Availability of own investment up to 2m€ per project allows us to reach the next value milestone.